Di Yang | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Di Yang | Cardiovascular Pharmacology | Best Researcher Award

Fudan University | China

Assoc. Prof. Dr. Di Yang is a distinguished researcher in the field of cardiovascular pharmacology with an academic journey beginning at Harbin Medical University, where he completed both his B.S. and M.S. degrees in Pharmacy and Pharmacology, respectively, followed by a Ph.D. in Cardiovascular Pharmacology from the School of Pharmacy, Fudan University. Currently serving as an Associate Professor at the Human Phenome Institute, Fudan University, Dr. Yang has developed a remarkable research career with postdoctoral training at Fudan University’s Basic Medical Sciences and an extensive record of competitive research grants, including multiple projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Science and Technology Commission. His innovative work spans vascular biology, cardiovascular aging, epigenetics, and metabolic disorders, focusing on critical mechanisms involving pyruvate dehydrogenase kinase 4, histone methyltransferases SMYD2 and SMYD3, and m6A demethylase ALKBH5 in vascular remodeling, endothelial aging, and cardiac hypertrophy. As a prolific author, Dr. Yang has contributed significantly to high-impact journals with key publications such as The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy, Poly (ADP-ribose) polymerases 16 triggers pathological cardiac hypertrophy via activating IRE1α-sXBP1-GATA4 pathway, Histone methyltransferase Smyd2 drives vascular aging by its enhancer-dependent activity, Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation, H3K4 methyltransferase Smyd3 mediates vascular smooth muscle cell proliferation, migration and neointima formation, The histone methyltransferase DOT1L is a new epigenetic regulator of pulmonary fibrosis, Histone methyltransferase Smyd3 is a new regulator for vascular senescence.

Profile: Orcid

Featured Publications

Chen, M., & Yang, D. (2025). Current insights into obesity and m6A modification. Biomedicines, 13(9), 2164.

Chen, M., Su, H., Shu, M., Shen, F., Lu, Y., Wu, S., Su, Z., Yu, M., & Yang, D. (2024). The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy. Cell Death & Disease, 15, 285.

Su, H., Xu, J., Su, Z., Xiao, C., Wang, J., Zhong, W., Meng, C., Yang, D., & Zhu, Y. (2023). Poly (ADP-ribose) polymerases 16 triggers pathological cardiac hypertrophy via activating IRE1α–sXBP1–GATA4 pathway. Cellular and Molecular Life Sciences, 80, 159.

Su, H., Meng, C., Xu, J., Su, Z., Xiao, C., & Yang, D. (2022). Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation. Cell Death & Disease, 13, 899.

Jinyu Liu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Jinyu Liu | Drug Discovery and Development | Best Researcher Award

School of Public Health Jilin University | China

Mr. Jinyu Liu is a distinguished scholar in the fields of stem cell biology, regenerative medicine, toxicology, tissue engineering, and tumor pathobiology. He began his academic journey at the N. Bethune University of Medical Sciences, where he successfully completed his MD, followed by a Master’s degree in Toxicology and a Ph.D. in Biochemistry at the Institute of Regenerative Medicine. Building on this strong academic foundation, he embarked on an extensive research and teaching career across several leading institutions globally.Mr. Liu’s professional path includes serving as an Environmental Protection Engineer at the Songliao Water Conservancy Agency before moving into academic research and teaching. He held research positions at Zurich University Hospital in Switzerland, where he contributed significantly to studies in dermatology and regenerative medicine, followed by a research faculty position at the State University of New York at Buffalo in the Department of Biological and Chemical Engineering. Returning to China, he joined Jilin University, holding roles such as Vice Chair of the Department of Pathobiology, Chair of the Department of Toxicology, and later Professor at the School of Public Health, where he continues to teach and mentor future scientists.Throughout his career, Mr. Liu has contributed extensively to scientific literature with publications spanning diverse research areas. His works include studies on PBX1 attenuating MeHg-induced SH-SY5Y cell apoptosis, AT-PBX1 fusion protein alleviating LPS-induced acute lung injury, and viral hijacking of host DDX60 promoting Crimean-Congo hemorrhagic fever virus replication. He has explored type 3 diabetes and metabolic reprogramming of brain neurons, neurotoxic β-amyloid oligomers causing mitochondrial dysfunction in neurons, and research on the development and regeneration of hair follicles. His studies have also examined circadian clock regulation in hair follicle cycles, the role of PBX1 in mammalian kidneys, oxidative stress modulation in mesenchymal stem cells, and CRISPR-Cas12a-based detection of monkeypox virus.

Profile: Orcid

Featured Publications

Chen, Z., Liu, X., Zuo, K., Xin, Y., & Liu, J. (2025). TAT-PBX1 fusion protein alleviates LPS-induced acute lung injury via AMPK-TFAM signaling activation. Molecular Therapy.

Sui, Y., Marzi, A., Xu, Q., Liu, M., Liu, X., Liu, X., Wang, Y., Meng, X., Liu, Z., Li, Q., et al. (2025). Viral hijacking of host DDX60 promotes Crimean-Congo haemorrhagic fever virus replication via G-quadruplex unwinding. PLOS Pathogens, 21(6), e1013278.

Sui, Y., Liu, F., Zheng, S., Liu, X., Sun, P., Yao, C., Zhang, Y., Gao, H., Gao, X., & Liu, J. (2023). G-quadruplexes folding mediates downregulation of PBX1 expression in melanoma. Signal Transduction and Targeted Therapy, 8(1), 12.

Sui, Y., Xu, Q., Liu, M., Zuo, K., Liu, X., & Liu, J. (2022). CRISPR-Cas12a-based detection of monkeypox virus. Journal of Infection, 85(6), 702–769.

Ma, Y., Li, M., Liu, J., Pang, C., Zhang, J., Li, Y., & Fu, X. (2018). Location, isolation, and identification of mesenchymal stem cells from adult human sweat glands. Stem Cells International, Article ID 2090276.

Stephano Hanolo Mlozi | Herbal Medicine and Nutraceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Stephano Hanolo Mlozi | Herbal Medicine and Nutraceuticals | Best Researcher Award

Mkwawa University College of Education | Tanzania

Dr. Stephano Hanolo Mlozi is a Senior Lecturer in Chemistry at the University of Dar es Salaam, based at Mkwawa University College of Education in Iringa, Tanzania. He is part of the Department of Chemistry and specializes in Organic Chemistry, with a strong research focus on Natural Products. Dr. Mlozi pursued his Bachelor of Science with Education, majoring in Chemistry and Biology, followed by a Master of Science at the University of Dar es Salaam. He then obtained his PhD from The Nelson Mandela African Institution of Science and Technology. As a committed academic and researcher, he teaches a wide range of undergraduate and postgraduate courses, including Organic Chemistry, Organic Spectroscopy, Biochemistry, Chemo-Ecology, General Chemistry, and Chemistry of Natural Products.Dr. Mlozi’s research interests revolve around Natural Products and Antimicrobial Bio-prospecting, Herbal Drug Formulations, Biofuels, Environmental Sciences, and Chemo-Ecology, making significant contributions to the fields of medicinal plant research and bioactive compound discovery. His publications demonstrate extensive expertise in natural product chemistry and its biomedical applications. Some of his notable works include Biogas Generation from Food Waste through Anaerobic Digestion Technology with Emphasis on Enhancing Circular Economy in Sub-Saharan Africa – A Review, Phytochemistry and Biosynthesis of Phytochemical: In Ethnobotany and Ethnopharmacology of Medicinal and Aromatic Plants – Steps Towards Drug Discovery, Seasons and Bee Foraging Plant Species Strongly Influence Honey Antimicrobial Activity, and Plant Diversity and Honeybees’ Foraging Preferences: An Implication for Honeybees’ Conservation.His research also includes experimental studies such as In vitro Evaluation of the Herbal Cream Formulation from Methanolic Leaf Extracts of Tephrosia vogelii Hook.f for Topical Application, GC-MS Analysis of Bioactive Phytochemicals from Methanolic Leaf and Root Extracts of Tephrosia vogelii, and The Role of Natural Products from Medicinal Plants against COVID-19: Traditional Medicine Practice in Tanzania. Dr. Mlozi has further explored pharmacological and toxicological aspects in works like The In Vivo Toxicity Evaluation of Leaf and Root Methanolic Extracts of Tephrosia vogelii Hook.f using Animal Model and Antimicrobial Activities of Tephrosia vogelii against Selected Pathogenic Fungi and Bacteria Strains. His earlier contributions include studies such as Topical Application of Juices from Fresh Leaves of Lycopersicon esculentum against Fungal Skin Infections in Tanzania and Antimycobacterial and Antibacterial Activities of Extracts from Selected Medicinal Plants in Tanzania, which have laid the foundation for his subsequent research advancements.

Profile: Orcid

Featured Publications

Seasons and bee foraging plant species strongly influence honey antimicrobial activity. Journal of Agriculture and Food Research.

In vitro evaluation of the herbal cream formulation from methanolic leaf extracts of Tephrosia vogelii Hook.f for topical application. Clinical Phytoscience.

GC-MS analysis of bioactive phytochemicals from methanolic leaf and root extracts of Tephrosia vogelii. Scientific African.

The role of natural products from medicinal plants against COVID-19: Traditional medicine practice in Tanzania. Heliyon.

The in vivo toxicity evaluation of leaf and root methanolic extracts of Tephrosia vogelii Hook.f using animal model. Clinical Phytoscience.

Antimicrobial activities of Tephrosia vogelii against selected pathogenic fungi and bacteria strains. Mycology.

Topical application of juices from fresh leaves of Lycopersicon esculentum against fungal skin infections in Tanzania. MOJ Current Research & Reviews.

Antimycobacterial and antibacterial activities of extracts from Caesalpinia bonduc (L.) Roxb.

Ismail Sulaiman | Herbal Medicine and Nutraceuticals | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Mr. Ismail Sulaiman | Herbal Medicine and Nutraceuticals | Top Pharmaceutical Scientist Award

Kebbi State University of Science and Technology | Nigeria

Mr. Ismail Sulaiman is a dedicated and emerging researcher in the field of biochemistry and molecular biology, with a strong academic and research foundation in metabolic disorders, neuroprotection, and nutritional interventions. He has pursued a progressive academic path, beginning with a National Diploma in Science Laboratory Technology, followed by a Higher National Diploma in Biochemistry, a Professional Diploma in Education, and advanced degrees culminating in a Postgraduate Diploma and a Master’s in Biochemistry. Throughout his academic training, he consistently demonstrated excellence in research methodologies, laboratory techniques, and scientific writing, equipping him with the skills necessary to address complex biomedical challenges.His research journey gained significant momentum during his role as a Graduate Research Assistant at the Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, where he worked on several impactful projects under the supervision of eminent scholars such as Prof. Mustapha Umar Imam and Dr. Muhammad Hassan Yankuzo. One of his major research focuses was the “Effect of Brown Rice Consumption on Iron-Induced Parkinson’s Disease in Drosophila melanogaster,” where he contributed to designing pilot studies, performing locomotive activity assessments, conducting biochemical analyses, and designing primers for metabolic gene studies. Additionally, he played a vital role in research exploring the “Effect of Jatropha on High-Sugar Diet-Induced Type 2 Diabetes Mellitus,” emphasizing nutritional and biochemical interventions in metabolic disorders. His involvement in the study titled “Effect of Maternal, Paternal and Parental Iron Deficiency and Rapamycin Supplementation on Offspring in Drosophila melanogaster” demonstrated his interest in epigenetics, metabolic health, and intergenerational nutritional effects.

Profile: Orcid

Featured Publications

Sulaiman, I., Uhuami, A. O., Yahaya, B., Yusuf, A. J., & Imam, M. U. (2025). Methanolic Jatropha tanjonesis leaf extract mitigates high-sugar diet-induced metabolic dysfunction in male Drosophila melanogaster.

Faruk, S., Ibrahim, K. G., Abbas, A. Y., Sulaiman, I., & Imam, M. U. (2025). Paternal iron deficiency and rapamycin supplementation influence antioxidants status, autophagy and lifespan in Drosophila melanogaster. Journal of Trace Elements in Medicine and Biology.

Faruk, S., Ibrahim, K. G., Abbas, A. Y., Sulaiman, I., & Imam, M. U. (2025). Rapamycin and post-deficiency dietary recovery reshape antioxidant response and survival in offspring of iron-deficient mothers. Biological Trace Element Research.

Faruk, S., Ghandi, K. I., Abbas, A. Y., Sulaiman, I., & Imam, M. U. (2025). Maternal iron deficiency modulates antioxidant status and longevity in a sex-dependent manner in Drosophila melanogaster.

Yankuzo, H. M., Sulaiman, I., Muhammad, S. A., Raji, A. A., Uthman, Y. A., & Imam, M. U. (2024). Brown rice attenuates iron-induced Parkinson’s disease phenotypes in male wild-type Drosophila: Insights into antioxidant and iron metabolism modulation. Applied Physiology, Nutrition, and Metabolism.

Uthman, Y. A., Ibrahim, K. G., Abubakar, M. B., Sulaiman, I., & Imam, M. U. (2024). Neuroprotective effects of brown rice consumption in an iron-induced parkinsonism in Drosophila. Nutritional Neuroscience.

Muhammad, S., Abubakar, A., Rabiu, S., & Sulaiman, I. (2018). Antioxidant content and in vitro diphenylpicrylhydrazyl free radical scavenging activity of selected medicinal plants. Journal of Intercultural Ethnopharmacology.

Nadira Aitambaeva | Formulation Science | Best Research Article Award

Published on by Top Pharmaceutical

Dr. Nadira Aitambaeva | Formulation Science | Best Research Article Award

Kazakh National Medical University | Kazakhstan

Dr. Nadira Aitambaeva is a distinguished public health professional and academician whose career embodies a strong commitment to advancing healthcare systems and population well-being in Kazakhstan. She began her academic journey at the Kazakh National Medical University named after S.D. Asfendiyarov, earning her Bachelor’s degree in Public Health, where she developed a solid foundation in epidemiology, healthcare policy, and preventive medicine. Her passion for public health led her to pursue a Master’s degree at the Kazakhstan School of Public Health, where she deepened her expertise in health promotion, disease prevention, and healthcare management. Determined to contribute to health research and policy on a broader scale, she achieved a Doctor of Public Health degree from the same institution, specializing in population health, health systems research, and public health education.Dr. Aitambaeva has dedicated her professional career to teaching at the Department of Population Health and Social Sciences at the Kazakhstan School of Public Health, where she continues to shape the next generation of public health professionals. Her teaching focuses on integrating theoretical knowledge with practical applications, ensuring students gain the analytical skills necessary to address modern public health challenges. Through her mentorship, she has fostered a research-oriented environment that encourages evidence-based decision-making in healthcare delivery and policy formation.

Profile: Orcid

Featured Publications

Aitambayeva, N. N., Svetlanova, S., Kumar, A. B., Makhanbetkulova, D. N., Aurelija, B., Suleymenov, M. S., & Nazarova, L. Z. (2025). The impact of artificial intelligence on the standardization and improvement of nursing care. Фтизиопульмонология, 47(12), 27.

Aitambayeva, N. N., Aringazina, A. M., Nazarova, L. Z., Adenov, M. M., & Ismailov, Sh. Sh. (2025). Level of awareness of decision-makers on tuberculosis issues: Results of a qualitative study. Фтизиопульмонология, 20(15), 21.

Nazarova, L. Z., Nurbakyt, A. N., Zhakupova, M. N., Aitambayeva, N. N., Svetlanova, Sh. M., Saktapov, A. K., & Narymbaeva, N. N. (2024). Medical and social consequences of iodine deficiency diseases of the thyroid gland. Фтизиопульмонология, 15(82), 11.

Akhmetov, V. I., Kamaliev, M. A., Brimzhanova, M. D., Moiyinbaeva, Sh. M., Ramazanova, M. A., Narymbaeva, N. N., & Aitambayeva, N. N. (2024). Towards high-quality medical care through improvement of medical education. Наука и здравоохранение, 26(2), 25.

Tleuberlin, T. K., Glushkova, N. E., Aitambayeva, N. N., Zhusupov, S. M., Kazangapov, R. S., & Abdrakhmanov, S. T. (2023). Development of an algorithm for dispensary observation of patients after coronary artery bypass grafting. Наука и здравоохранение, 25(5), 29.

Aringazina, A. M., Aitambayeva, N. N., Nazarova, L. Z., Alimbekova, G. T., Ismailov, Sh. Sh., Adenov, M. M., Dzhazybekova, P. M., Musabekova, G. A., & Alikeeva, E. A. (2021). Awareness of the population and key groups in Kazakhstan about tuberculosis. Наука и здравоохранение, 23(5), 8.

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile 

Orcid

Education 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof. Dr. Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Ebrictus Group at IDIAP Jordi Gol | Spain

Assist. Prof. Dr. JL Clua-Espuny is a distinguished academic and healthcare professional with extensive experience in medicine, primary healthcare, and medical education. He has served in various leadership and academic roles across prestigious institutions, including Universitat Rovira i Virgili, Universidad Miguel Hernández de Elche, and the Institut Català de la Salut. His expertise spans family medicine, health policy, and clinical research, with a strong commitment to improving patient care and medical training. Throughout his career, he has mentored numerous doctoral candidates, contributed to healthcare policy initiatives, and advanced research in cardiovascular diseases, primary care innovation, and public health strategies.

Publication Profile 

Orcid

Education 

Assist. Prof. Dr. JL Clua-Espuny holds multiple advanced degrees, including a Doctorate in Medicine and a Master’s in Primary Care from Universidad Miguel Hernández de Elche. He also completed specialized master’s programs in Health Economics and Healthcare Management from the University of Barcelona and advanced training in Quality Management at Universidad Autonoma de Barcelona and Fundació Avedis Donabedian. Additionally, he earned postgraduate diplomas in Primary Care Management and Quality Evaluation Methodologies and holds dual degrees in Medicine and Philosophy/Psychology from the University of Barcelona. His academic path reflects a dedication to integrating medical, administrative, and research excellence to improve healthcare delivery systems.

Experience 

Assist. Prof. Dr. JL Clua-Espuny career spans healthcare, academia, and research. He served as Director of Primary Care at the Institut Català de la Salut, Vice-President of the Health Council in Tortosa, and Coordinator of Health Plans for the Catalan Health Service. In academia, he has been a professor and tutor at Universitat Rovira i Virgili and Universidad Miguel Hernández de Elche, guiding numerous doctoral and master’s theses. His research affiliations include the Institut Recerca IDIAP Jordi Gol. He has combined clinical practice, academic instruction, healthcare leadership, and policy planning, contributing significantly to primary care innovations and medical education reforms in Spain.

Awards and Honors 

Assist. Prof. Dr. JL Clua-Espuny has received multiple honors for his contributions to medicine, education, and research. He earned the Premio Extraordinario de Doctorado for academic excellence and has been recognized for advancing primary healthcare research and education in Catalonia. His leadership roles in healthcare institutions and medical associations highlight his influence in shaping health policy and service delivery. He has been invited to collaborate in national and regional healthcare planning, reflecting his reputation as an expert in primary care management and cardiovascular health research. His mentorship of numerous doctoral theses further illustrates his commitment to academic excellence and professional development.

Research Focus 

Assist. Prof. Dr. JL Clua-Espuny research centers on primary healthcare, cardiovascular disease prevention, public health interventions, and healthcare quality improvement. He has led and collaborated on projects investigating atrial fibrillation, ischemic stroke, heart failure, and healthcare service optimization. His work often bridges clinical practice with public health policy, emphasizing early detection, risk stratification, and health outcomes in community settings. He has contributed extensively to evaluating the economic impact of chronic diseases, vaccination strategies, and integrated care models. His multidisciplinary approach combines epidemiology, clinical research, and healthcare management to develop innovative strategies for improving patient outcomes and enhancing primary care systems.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Recent-onset atrial fibrillation: challenges and opportunities

Integrating Lung Ultrasound and the HEFESTOS Score in the Outpatient Heart Failure Management: A Prospective Cohort Study

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Abordaje extrahospitalario y hospitalario del ictus en fase aguda

Detección precoz de la fibrilación auricular a través de alteraciones en la onda P en el electrocardiograma (ECG) y la disfunción auricular en el ecocardiograma transtorácico (ETT) (póster)

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi.

Sex Disparities in the Direct Cost and Management of Stroke: A Population-Based Retrospective Study

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review

Conclusion

Given his extensive research supervision, academic leadership, healthcare experience, and contributions to primary care and public health research, Assist. Prof. Dr. JL Clua-Espuny is highly suitable for the Best Researcher Award. His decades of service, combined with scientific innovation, educational mentorship, and healthcare leadership, position him as a strong candidate. By expanding global research collaborations and enhancing the international dissemination of his work, he could further elevate his impact in the field.

Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Published on by Top Pharmaceutical

Dr. Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Pharmacoepidemiologist at Sanofi | France

Dr. Sandrine Colas is a Senior Pharmacoepidemiologist with over a decade of expertise in pharmacoepidemiology, biostatistics, and real-world data research. She has led global pharmacovigilance initiatives, innovative AI-driven projects, and regulatory strategies at renowned institutions like Sanofi, IQVIA, and EPIPHARE-ANSM. With extensive experience in risk-benefit assessment, AI and NLP applications in healthcare, and cross-functional collaboration, she has significantly impacted regulatory decision-making and scientific dissemination. Dr. Colas is widely recognized for her operational excellence, leadership, and contributions to real-world evidence studies, presenting at major scientific forums and mentoring future experts in pharmacoepidemiology and public health research.

Publication Profile 

Orcid

Education 

Dr. Sandrine Colas holds a Ph.D. in Public Health, Epidemiology from Université Paris-Saclay, where she specialized in pharmacoepidemiology and advanced biostatistics. She also earned an MSc in Public Health, Epidemiology from Université Paris-Sud and another MSc in Food Industries Technologies from ENSAIA, strengthening her interdisciplinary foundation. Additionally, she completed a degree in Biomedical Engineering at UTC/ENSP, gaining technical and analytical expertise essential for healthcare data analysis and medical research. This diverse educational background has enabled her to integrate statistical modeling, real-world data analytics, and public health perspectives to address complex issues in drug safety and healthcare innovation.

Experience 

Dr. Sandrine Colas currently serves as Senior Pharmacoepidemiologist at Sanofi R&D, leading the Valproate PASS Program, TANGO study, and AI-based healthcare innovations while collaborating with PRAC/EMA regulatory bodies. She previously directed epidemiological research at IQVIA, managing real-world evidence studies and regulatory responses. At EPIPHARE-ANSM, she contributed to post-authorization safety studies (PASS), risk management plans (RMPs), and mentored postgraduate students. Across roles, she has excelled in cross-functional collaboration, strategic leadership, scientific presentations, and regulatory submissions. Her work integrates real-world evidence, AI analytics, and clinical data insights, shaping global pharmacovigilance practices and improving drug safety monitoring in real-world healthcare settings.

Awards and Honors 

Dr. Sandrine Colas has received multiple recognitions for her leadership and scientific contributions. At Sanofi, she earned the 2022 Development Award for Operational Excellence and Outstanding Impact Awards in 2022 and 2024 for her role in AI-driven pharmacovigilance innovations. Her pioneering work on AI-NLP-LLM applications in healthcare research was ranked among the Top 5% Abstracts at ISPOR 2024, where she also won the Best Podium Award. She has presented widely at international conferences including ISPE, EBMT, and ISPOR, reflecting her commitment to advancing pharmacoepidemiology, regulatory science, and real-world data analytics through high-impact publications and innovative research methodologies.

Research Focus 

Dr. Sandrine Colas specializes in pharmacoepidemiology, regulatory science, and real-world data analytics. Her research focuses on drug safety, post-authorization studies, and risk-benefit assessments using large healthcare datasets like SNDS. She has integrated AI, natural language processing (NLP), and advanced analytics to enhance drug surveillance, predict adverse outcomes, and support regulatory decision-making. Her interests also include AI-driven pharmacovigilance innovations, real-world evidence generation, and methodological advancements in epidemiological research. Through cross-disciplinary collaboration, she aims to strengthen evidence-based regulatory policies, optimize patient safety strategies, and bridge the gap between clinical research, real-world practice, and global health policy in pharmaceutical development.

Publication Top Notes

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries

Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine

Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France

Exchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients

Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients

Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship

Inondation des capteurs de pression sanguine des générateurs–moniteurs d’hémodialyse

Conclusion

Given her leadership in pharmacovigilance research, AI-based healthcare innovations, and extensive real-world data studies, Dr. Sandrine Colas is a strong candidate for the Pharmaceutical Research Impact Award. Her impactful publications, regulatory contributions, and commitment to improving drug safety and healthcare decision-making reflect the award’s core values. With minor expansions into emerging interdisciplinary fields, she could further solidify her status as a global leader in pharmaceutical research innovation and evidence-based healthcare advancements.

Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Doctor at Ministry of Health | Spain

Dr. Pedro Moltó-Balado is a dedicated medical professional currently associated with the Ministry of Health, Spain. With a background in family and community medicine, he has combined clinical expertise with research innovation to advance patient care processes and public health initiatives. He has pursued advanced studies in biomedicine, patient care management, and headache specialization while contributing extensively to scientific publications across medical disciplines. His work encompasses cardiovascular health, mental health, primary care innovations, and clinical risk assessment, with a strong commitment to integrating machine learning and advanced diagnostic strategies in healthcare to enhance patient outcomes and medical decision-making.

Publication Profile 

Orcid

Education 

Dr. Pedro Moltó-Balado holds a Graduate in Medicine from Terres de l’Ebre Teaching Unit, Catalonia, Spain. He specialized in Family and Community Medicine through Francisco de Vitoria University and pursued a Ph.D. in Biomedicine from Rovira i Virgili University. Additionally, he completed postgraduate certifications as a University Expert in Headaches and in the Management of Patient Care Processes from Jaime I University and the University of Valencia, respectively. He has undergone specialized health training and participated in continuous academic development across medical law, healthcare management, and clinical research, strengthening his expertise in multidisciplinary healthcare and evidence-based medical practices.

Experience 

Dr. Pedro Moltó-Balado has been actively involved in healthcare practice and academic research through the Ministry of Health and academic institutions in Spain. He has contributed as a corresponding author and researcher in multiple peer-reviewed scientific journals, focusing on primary care innovations, cardiometabolic diseases, and neurological conditions. His professional engagements include clinical research in atrial fibrillation, stroke prevention, metabolic disorders, and rare medical conditions, along with implementing patient-centered healthcare strategies. He has also participated in academic teaching, supervising research projects, and contributing to medical education programs while collaborating with healthcare organizations to translate clinical research into practical healthcare solutions.

Awards and Honors 

Dr. Pedro Moltó-Balado has been recognized for his research contributions and academic excellence in family and community medicine, cardiometabolic health, and primary care innovation. His work on early diagnosis in cardiovascular medicine, clinical risk prevention, and rare disease case studies has been acknowledged through conference presentations, academic collaborations, and peer-reviewed scientific publications. He has contributed to international research forums and interdisciplinary projects that integrate clinical practice with technological innovation, including machine learning applications in healthcare. His commitment to advancing evidence-based medical practices has earned him recognition in medical research communities focused on improving public health outcomes.

Research Focus 

Dr. Pedro Moltó-Balado’s research focuses on cardiovascular risk prediction, primary care optimization, and integrating technology into clinical diagnostics. His studies explore early detection of atrial fibrillation, stroke prevention strategies, metabolic disorders, and neurological complications in primary healthcare settings. He has worked on machine learning models for predicting major adverse cardiovascular events, case studies on rare conditions such as pheochromocytoma and rhinocerebral mucormycosis, and management approaches for psychiatric medication complications. His multidisciplinary approach bridges clinical medicine, data analytics, and patient care strategies, aiming to develop innovative diagnostic tools and risk assessment methods that improve healthcare decision-making and patient safety outcomes.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Algo más que una coxalgia: necrosis avascular de cabeza femoral

Aripiprazole: Beware of pathological gambling addiction,Aripiprazol: cuidado con la adicción patológica al juego

Mucormicosis tras una picadura de araña

The Future of Healthcare: Biomedical Technology and Integrated Artificial Intelligence

Oleoma glúteo: consecuencias del tratamiento intramuscular

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation

Conclusion

Dr. Pedro Moltó-Balado’s academic achievements, innovative research in cardiometabolic and primary care medicine, and integration of technology into clinical diagnostics make him a highly suitable candidate for the Best Researcher Award. His dedication to improving patient outcomes through evidence-based research and his contributions to medical literature align well with the award’s objectives. With continued emphasis on global collaborations and translational research, his work has the potential to make significant advancements in public health and medical science.